5 years ago

Amphista Therapeutics Raises $7.5 Million for Oncology Pipeline Advancement

  • Amphista Therapeutics, a Glasgow, Scotland-based biopharmaceutical company, has secured $7.5 million in Series A funding led by Advent Life Sciences

  • The funding will be used to advance Amphista's oncology pipeline to the clinic

  • The company's technology focuses on developing cancer therapeutics that harness the body's natural processes to degrade and remove disease-causing proteins.

      • ProblemHealthcare

      "Current cancer therapies are often ineffective or have harmful side effects because they target the wrong proteins or cannot reach the target protein effectively."

      Solution

      "Amphista Therapeutics has developed a new platform that uses small molecules to specifically target and degrade disease-causing proteins. This allows for more precise and effective cancer treatment with fewer side effects."

      Covered on